All In Biotech

BLA 761208 · Seagen

Tivdak

Tisotumab Vedotin-Tftv · Injection

NovelAccelerated approvalPriority review

CDER novel approval, Sep 20, 2021: To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Sep 20, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

13

2 Phase 3, 1 recruiting

FAERS reports

971

609 serious, 81 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: OCULAR TOXICITY • TIVDAK can cause severe ocular toxicities resulting in changes in vision, including severe vision loss, and corneal ulceration. [see Warnings and Precautions (5.1) ]. • Conduct an ophthalmic exam, including an assessment of ocular symptoms, visual acuity, and slit lamp exam of the anterior segment of the eye prior to initiation of TIVDAK, prior to every cycle for the first nine cycles, and as clinically indicated. [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . • Adhere to the required premedication and eye care before, during, and after infusion. [see Dosage and Administration (2.2) ]. • Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ]. WARNING: OCULAR TOXICITY See full prescribing information for...

What it is approved for

From the label in effect Oct 16, 2026.

TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. ( 1 )

Mechanism: Tisotumab vedotin-tftv is a tissue factor (TF)-directed antibody drug conjugate (ADC). The antibody is a human IgG1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggests that the anticancer activity of tisotumab vedotin-tftv is due to the binding of the ADC to TF expressing cancer cells, followed by internalization of the ADC-TF complex, and release of MMAE via proteolytic cleavage. MMAE disrupts...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 2024 Supplement 7 · Efficacy · priority review LabelLetter
  • Sep 20, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
1 products under this application
  • TIVDAK · TISOTUMAB VEDOTIN-TFTV 40MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tisotumab Vedotin" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression80
  • neuropathy peripheral79
  • nausea66
  • dry eye55
  • conjunctivitis52
  • rash47
  • off label use42
  • death40
  • diarrhoea40
  • anaemia35
  • fatigue34
  • eye disorder31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20196
202014
202124
2022172
2023186
2024182
2025232
2026155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tivdak (Tisotumab Vedotin-Tftv)

2024 spending

$1.1M

Beneficiaries

n/a

45 claims

Per beneficiary

n/a

$6,724.68 per unit

View as table
YearSpending
2020$0
2021$0
2022$400,835
2023$703,742
2024$1,129,746

Part B: Tivdak (TIsotumab Vedotin-Tftv) · HCPCS J9273

2024 spending

$16.2M

Beneficiaries

189

765 claims

Per beneficiary

$85,824

2024 ASP limit $174.91 per unit

View as table
YearSpending
2020$0
2021$0
2022$6,726,328
2023$11,221,550
2024$16,220,713

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.